AML Treatment in 2026: Venetoclax, IDH Inhibitors, and Targeted Therapy

Research-informed explainer — last updated April 12, 2026

Acute myeloid leukemia (AML) treatment has been fundamentally rewritten over the past decade: patients who were once considered too old or too frail for any meaningful therapy now have access to venetoclax-based oral combinations that produce remission rates exceeding 60%, while patients with specific mutations — IDH1, IDH2, or FLT3 — can receive targeted drugs designed precisely for their disease's molecular defect. The right treatment starts with knowing the genetics of your AML.

This article draws on research from five leukemia specialists at leading academic centers. Courtney DiNardo, MD, Professor in the Division of Cancer Medicine at MD Anderson Cancer Center, led the landmark VIALE-A trial of venetoclax plus azacitidine (2,663 citations), the ivosidenib IDH1 inhibitor trial (1,382 citations), and contributed to the 2022 ELN AML guidelines (2,788 citations) — three papers that collectively define current AML care. Martin Tallman, MD, Director of Faculty Mentorship at Northwestern's Lurie Cancer Center and former Chief of the Leukemia Service at Memorial Sloan Kettering, led the 2017 ELN recommendations (5,802 citations), the 2009 prior guidelines (3,383 citations), and published foundational work on IDH1/IDH2 mutations (2,713 citations). Daniel DeAngelo, MD, PhD, Chief of the Division of Leukemia at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School, published the enasidenib trial for IDH2-mutant AML (1,447 citations). Mark Litzow, MD, Professor of Medicine at Mayo Clinic, published the pivotal integrated genetic profiling study in AML (1,935 citations) and dose-intensification data (902 citations) that explain why the same diagnosis leads to different treatments. Michael Savona, MD, Beverly and George Rawlings Director of Hematology Research and Professor of Medicine at Vanderbilt University, published on venetoclax plus low-dose cytarabine for older AML patients (694 citations).

Why genetics determines your AML treatment

AML is not one disease — it is a collection of molecularly distinct diseases that happen to look similar under the microscope. The ELN (European LeukemiaNet) guidelines co-authored by Dr. Tallman in 2017 (5,802 citations) and updated with Dr. DiNardo's contribution in 2022 (2,788 citations) classify AML into favorable, intermediate, and adverse risk categories based on cytogenetic abnormalities and mutations. These categories directly determine whether intensive chemotherapy is the right approach, whether a transplant is needed in first remission, and whether targeted drugs can be added.

Dr. Litzow's 2012 paper in the New England Journal of Medicine (1,935 citations) demonstrated that integrated genetic profiling — looking at DNMT3A mutations, NPM1 mutations, and MLL translocations together — predicted which patients benefited most from high-dose induction chemotherapy. This work helped explain the clinical observation that two patients with seemingly identical AML could have dramatically different outcomes.

Key mutations that guide therapy today include:

• FLT3: Found in approximately 25–30% of AML cases; FLT3 inhibitors (midostaurin, quizartinib, gilteritinib) are added to or replace chemotherapy in these patients
• IDH1: Present in ~7–10%; targeted by ivosidenib
• IDH2: Present in ~10–12%; targeted by enasidenib
• NPM1: A favorable marker that shapes treatment intensity decisions
• TP53: Adverse; associated with poor outcomes on standard therapy

Standard intensive induction: "7+3" and its refinements

For younger, fit patients with newly diagnosed AML, standard induction chemotherapy has for decades been the "7+3" regimen: seven days of continuous cytarabine infusion plus three days of an anthracycline (typically daunorubicin or idarubicin). The goal is to achieve complete remission — less than 5% blasts in the marrow.

Dr. Litzow contributed to the ECOG-ACRIN E1900 trial published in the New England Journal of Medicine in 2009 (902 citations), which showed that intensifying the daunorubicin dose from 45 mg/m² to 90 mg/m² significantly improved complete remission rates (71% vs. 57%) and overall survival in patients under 60. High-dose daunorubicin became the standard for younger patients based on this trial.

Venetoclax plus hypomethylating agents: the treatment for older patients

Until 2018, older adults with AML — defined for treatment purposes as those over 75 or those with significant comorbidities — had essentially no good options. Intensive chemotherapy was too toxic, and hypomethylating agents (azacitidine, decitabine) alone produced remission rates of only 20–30%.

Venetoclax, a BCL-2 inhibitor that forces malignant cells into apoptosis, changed this equation when combined with hypomethylating agents. Dr. DiNardo's phase 1b/2 study published in Blood in 2018 (1,826 citations) enrolled 145 patients aged 65 and older who were ineligible for intensive chemotherapy. The complete remission or complete remission with incomplete count recovery (CR/CRi) rate was 68% with venetoclax 400 mg combined with either azacitidine or decitabine — double the rate seen historically with hypomethylating agents alone.

The definitive VIALE-A trial, led by Dr. DiNardo and published in the New England Journal of Medicine in 2020 (2,663 citations), enrolled 431 patients ineligible for intensive chemotherapy. Venetoclax plus azacitidine produced a CR/CRi rate of 66.4% versus 28.3% for azacitidine alone, with a median overall survival of 14.7 months versus 9.6 months. For patients with IDH1 or IDH2 mutations, the results were even better — 75% responded. This trial established venetoclax-azacitidine as the standard of care for older or unfit AML patients.

Dr. Savona's group also published results from venetoclax plus low-dose cytarabine (LDAC) for older untreated patients (694 citations), showing a CR/CRi rate of 54% — another option for patients who cannot tolerate azacitidine.

IDH inhibitors: targeted therapy for a specific subgroup

IDH1 and IDH2 mutations produce a neomorphic enzyme activity that generates 2-hydroxyglutarate, an oncometabolite that blocks hematopoietic differentiation. Dr. Tallman's group published the mechanistic study explaining this in Cancer Cell in 2010 (2,713 citations). Reversing this block with an IDH inhibitor causes malignant cells to differentiate into mature, non-dividing cells — a biologically distinct mechanism from cytotoxic chemotherapy.

Ivosidenib targets IDH1. Dr. DiNardo published the pivotal trial in the New England Journal of Medicine in 2018 (1,382 citations): among 125 patients with IDH1-mutant relapsed or refractory AML, ivosidenib 500 mg daily produced a response rate of 41.6%, with durable complete remissions in a subset and meaningful transfusion independence. Ivosidenib has since received first-line approval in combination with azacitidine for IDH1-mutant patients ineligible for intensive chemotherapy.

Enasidenib targets IDH2. Dr. DeAngelo contributed to the phase 1/2 trial published in Blood in 2017 (1,447 citations): in 199 patients with IDH2-mutant relapsed or refractory AML, enasidenib produced an overall response rate of 40.3%, with a median overall survival of 9.3 months — meaningful in this heavily pretreated population. A notable feature of IDH inhibitor responses is the "differentiation syndrome" — a potentially serious inflammatory reaction as malignant cells mature — which requires vigilant monitoring and corticosteroid management.

Questions to ask your doctor

• Has my AML had a full next-generation sequencing panel performed to identify FLT3, IDH1/IDH2, NPM1, and TP53 mutations?
• Based on my age, health status, and AML genetics, am I a candidate for intensive induction chemotherapy or would venetoclax plus azacitidine be more appropriate?
• If I achieve complete remission, should I proceed to allogeneic stem cell transplant?
• Do I have an IDH1 or IDH2 mutation that would make me a candidate for a targeted inhibitor, either alone or in combination?
• What does minimal residual disease (MRD) testing tell us about my remission quality and relapse risk?
• What clinical trials are open for my AML subtype at this center?

The bottom line

AML treatment is now molecularly driven: the mutations in your leukemia cells determine whether you receive intensive chemotherapy, a targeted IDH or FLT3 inhibitor, or venetoclax combined with a hypomethylating agent. Older patients who previously had no good treatment option now achieve remission rates exceeding 65% with venetoclax-based regimens. Evaluation by a leukemia specialist who performs comprehensive molecular testing at diagnosis is the single most important step in ensuring access to the most effective available therapy.